BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1106 related articles for article (PubMed ID: 16259523)

  • 21. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
    Young JB
    Cardiol Clin; 1995 Aug; 13(3):379-90. PubMed ID: 7585774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Bissessor N; White H
    Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
    Maggioni AP; Fabbri G
    Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Lam CS; McEntegart M; Claggett B; Liu J; Skali H; Lewis E; Køber L; Rouleau J; Velazquez E; Califf R; McMurray JJ; Pfeffer M; Solomon S
    Eur J Heart Fail; 2015 Mar; 17(3):301-12. PubMed ID: 25655011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
    Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
    Prisant LM; Thomas KL; Lewis EF; Huang Z; Francis GS; Weaver WD; Pfeffer MA; McMurray JJ; Califf RM; Velazquez EJ
    J Am Coll Cardiol; 2008 May; 51(19):1865-71. PubMed ID: 18466801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR
    Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACE inhibitors in heart failure: prospects and limitations.
    Pitt B
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():285-90. PubMed ID: 9211022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
    Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring new treatment strategies in heart failure.
    Swedberg K
    Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.